Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin and Doxycycline for COVID-19 in Bangladesh
NCT04407130Phase 2Completed
- Sponsor
- icddr,b
- Start
- Jun 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CHILD-IVITAB and doxycycline in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by icddr,b. Primary endpoints: Duration of the virological clearance rate at 7 days, Days required for remission of fever at 7 days and 1 more. Started Jun 2020; status: completed.
02
Drugs
CHILD-IVITABdoxycycline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04407130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407130.